GSK Ups Ante In Triple COPD Therapy Race But Payers Wary
GSK is hoping its decision to bring forward the US filing of its triple combination therapy for patients with COPD will ensure it is the first to launch. But while physicians are keen to see it on the market, payers are wary.
You may also be interested in...
GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.
Novartis's recent publication of data from its FLAME study comparing its Ultibro Breezhaler with GSK's Advair/Seretide in reducing COPD exacerbations could lead to a change in guidelines to favor LAMA/LABAs over ICS/LABA products in patients with severe COPD. Boehringer Ingelheim's popular Stiolto Respimat will benefit from FLAME's good will, but GSK's son-of-Advair, Breo, will likely suffer.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.